RRN3P3: A Drug Target / Disease Biomarker (G100131998)

Target Name: RRN3P3

NCBI ID: G100131998

RRN3P3

Other Name(s): RRN3 pseudogene 3

RRN3P3: A Drug Target / Disease Biomarker

RRN3P3, also known as GPR300, is a G protein-coupled receptor (GPCR) that is expressed in various tissues and cells in the body. It is a potential drug target and has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

RRN3P3 is a member of the GPCR family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and hormone regulation.

RRN3P3 is a 3-dimensional protein with four transmembrane segments and a large extracellular region. It has a unique shape, with a long, linear N-terminus and a short, bent C-terminus. This shape allows it to interact with various signaling molecules, including G尾1, a protein that is involved in neurotransmitter signaling.

RRN3P3 has been shown to play a role in neurotransmitter signaling, particularly in the regulation of dopamine (D2) receptor function. D2 receptors are involved in motor coordination, mood regulation, and other physiological processes.RRN3P3 has been shown to interact with D2 receptors and regulate their function. This interaction between RRN3P3 and D2 receptors suggests that it may be a useful target for drugs that are designed to modulate neurotransmitter signaling.

RRN3P3 has also been shown to be involved in the regulation of psychiatric disorders. Studies have shown that individuals with certain psychiatric disorders, such as depression and anxiety, have lower levels ofRRN3P3 than healthy individuals. Additionally,RRN3P3 has been shown to interact with brain-derived neurotrophic factor (BDNF), a protein that is involved in the regulation of brain function and is often reduced in individuals with psychiatric disorders.

RRN3P3 has also been shown to be involved in cancer progression. Studies have shown that individuals with certain types of cancer, such as breast cancer and lung cancer, have lower levels ofRRN3P3 than healthy individuals. Additionally,RRN3P3 has been shown to interact with the protein PD-L1, which is involved in cancer cell survival and has been shown to promote the development of cancer.

In conclusion, RRN3P3 is a GPCR that has been shown to play a role in various physiological processes, including neurotransmitter signaling, psychiatric disorders, and cancer progression. As a potential drug target, RRN3P3 is a promising target for the development of new therapies for a wide range of diseases. Further research is needed to fully understand the role of RRN3P3 in cellular signaling and its potential as a drug target.

Protein Name: RRN3 Pseudogene 3

The "RRN3P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRN3P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets